SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, announced today that
members of its leadership team will be presenting at several events
in September, including:
- Rodman & Renshaw 18th Annual Global Investment
Conference
- Johnson & Johnson Innovation + JLABS Science 1st
Speaking Series
- Phacilitate Cell & Gene Therapy Europe 2017
- 2nd World Congress on Electroporation and Pulsed
Electric Fields in Biology, Medicine and Food & Environmental
Technologies
Rodman & Renshaw 18th Annual Global
Investment Conference
Punit
Dhillon, OncoSec's Chief Executive Officer, will present a
corporate overview at the Rodman & Renshaw
18th Annual Global Investment Conference on
September 11th at
10:25 AM ET at The Lotte New York
Palace Hotel in New York City.
Mr. Dhillon will be available to participate in one-on-one
meetings with investors who are registered to attend the
conference. If you are an institutional investor, and would
like to attend the Company's presentation or schedule a meeting,
please click on the following link: www.rodmanevents.com.
To view to the live webcast, please access the following link at
the time of the
presentation: http://wsw.com/webcast/rrshq27/oncs/. An
archived version of the webcast will be available for 90 days on
OncoSec's website: www.oncosec.com.
Johnson & Johnson Innovation + JLABS Science
1st Speaking Series
Tu
Diep, OncoSec's Vice President of Operations, will
participate in a panel discussion entitled: "Designing Nucleic Acid
Medicines" at the Johnson & Johnson Innovation + JLABS Science
1st Speaking Series on September
13th at 3:30 PM PT
at the JLABS in San Diego, CA. For
more information, please
visit: www.jlabs.jnjinnovation.com/events/coming.
Phacilitate Cell & Gene Therapy Europe 2017
Mr.
Diep will also participate in a panel discussion entitled: "
Non-Viral Delivery Platforms – Does the Latest Data Support
Widespread Ex Vivo and In Vivo Gene Therapy Application? " at the
Phacilitate Cell & Gene Therapy Europe 2017 on
September 21 at 11:30 AM CSET at the Maritim Proarte Hotel in
Berlin, Germany. For more
information, please visit: www.cgteurope.com.
2nd World Congress on Electroporation and Pulsed
Electric Fields in Biology, Medicine and Food & Environmental
Technologies
Shawna Shirley,
OncoSec's Senior Scientist, will present a poster entitled:
"Intratumoral Electroporation of Plasmid IL-12 Using Modified
Parameters and an Optimized DNA Plasmid Increases Immunogenicity in
Untreated Lesions in Mice" at the 2nd World Congress on
Electroporation and Pulsed Electric Fields on September 25 at 2:00 PM
ET at the Hilton Norfolk The Main in Norfolk, VA.
Adil Daud, MD, Chief Clinical
Strategist at OncoSec and Professor of Medicine at the University of California, San Francisco, will also
present a lecture during the "Electroporation Technologies for the
Treatment of Cancer" session on September
25 at 11:10 AM PT entitled:
"Local and Systemic Immunotherapy by Electroporation [OR-16]."
Alain Algazi, PhD, member of
OncoSec's Clinical Advisory Board and Professor of Medicine at the
University of California, San
Francisco, will present a plenary lecture on September 27 at 8:30 AM
ET entitled: "A Phase II Clinical Trial of Intratumoral
Plasmid IL-12 with Electroporation in Combination with
Pembrolizumab."
For more information, please
visit: https://wc2017.electroporation.net/.
About OncoSec Medical Incorporated:
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology, ImmunoPulse®,
for the treatment of cancer. ImmunoPulse® is designed to enhance
the local delivery and uptake of DNA-based immune-targeting agents,
such as IL-12. In Phase I and II clinical trials, ImmunoPulse®
IL-12 has demonstrated a favorable safety profile and evidence of
anti-tumor activity in the treatment of various solid tumors as
well as the potential to initiate a systemic immune response.
OncoSec's lead program, ImmunoPulse® IL-12, is currently in
clinical development for several indications, including metastatic
melanoma, and triple-negative breast cancer. The program's current
focus is on the significant unmet medical need in patients with
melanoma who are refractory or non-responsive to anti-PD-1/PD-L1
therapies. In addition to ImmunoPulse® IL-12, the Company is also
identifying and developing new immune-targeting agents for use with
the ImmunoPulse® platform. For more information, please
visit www.oncosec.com.
CONTACT:
Investor Relations
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
View original
content:http://www.prnewswire.com/news-releases/oncosec-announces-presentations-at-upcoming-investment-and-scientific-conferences-300515006.html
SOURCE OncoSec Medical Incorporated